[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amneal Pharmaceuticals (AMRX) Form 144 reports a proposed sale of 22,000 Class A shares through Merrill Lynch with an approximate sale date of 08/12/2025 and an aggregate market value of $198,000. The filing shows the shares were acquired on 03/03/2025 as equity compensation from Amneal Pharmaceuticals and that payment was made on the same date.

The filing lists 18,067,134 shares outstanding and indicates there were no securities sold by the person in the past three months. The filer also represents that they have no undisclosed material adverse information about the issuer.

Insights

Financial Analyst

TL;DR: Proposed sale is small in listed value and stems from recent equity compensation, suggesting limited market impact.

The filing discloses a proposed sale of 22,000 Class A shares with an aggregate market value of $198,000, to be executed through Merrill Lynch on or about 08/12/2025. The securities were acquired as equity compensation on 03/03/2025. From a trading-volume and valuation perspective, this notice documents an insider liquidity event rather than an operational development; it contains no earnings, guidance, or covenant changes. The absence of reported sales in the prior three months and the signer’s representation about undisclosed material information reduce near-term governance concerns.

Corporate Governance Expert

TL;DR: Routine Form 144 filing for insider sale tied to equity compensation; disclosure appears complete and procedural.

The document is a standard Form 144 notification showing the planned disposition of securities acquired by equity compensation. Broker details (Merrill Lynch) and the approximate sale date are provided, and the filer affirms no undisclosed material adverse information. There are no disclosures of prior sales in the past three months. As filed, the form meets Rule 144 procedural requirements and raises no immediate governance red flags based on the information provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
A	MERRILL LYNCH 157 CHURCH ST FL 26 NEW HAVEN CT 06510	22000	198000.00	18067134	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
A	03/03/2025	EQUITY COMPENSATION	AMNEAL PHARMACEUTICALS			22000	03/03/2025	EQUITY COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the AMRX Form 144 report?

The form reports a proposed sale of 22,000 Class A shares with an aggregate market value of $198,000, to be sold through Merrill Lynch on or about 08/12/2025.

How were the shares acquired according to the filing?

The shares were acquired on 03/03/2025 as equity compensation from Amneal Pharmaceuticals, with payment recorded on the same date.

How many Amneal shares are outstanding per the filing?

The filing lists 18,067,134 shares outstanding.

Were any securities sold by the filer in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale in the Form 144?

The broker named is Merrill Lynch at the address shown in the filing.